is a chronic, heterogeneous condition characterised by polyuria and polydipsia due to a deficiency of arginine vasopressin (AVP) secretion [1] . The most frequent aetiology is the destruction or degeneration of the neurons that originate in the supraoptic and paraventricular nuclei of the hypothalamus [1] . Mutations in the gene that encodes AVP have also been shown to be responsible for CDI [1, 2] . However, 30-50% of cases are considered idiopathic [3] .
Japan, intranasal desmopressin is currently used for the treatment of CDI. However, intranasal administration can be inconvenient or embarrassing, especially in public, and also involves uncertainty over dose level. The bioavailability of the intranasal desmopressin can be unpredictable in the presence of a blocked nose with rhinorrhoea (absorption decreased) or nasal hyperaemia (absorption increased) [4, 5] . Paediatric use of this route of administration is prone to greater variability in dosing; patients and parents are more likely to be unsure of adequate dosing and try to compensate, or achieve a better response, by administering more with the intranasal formulation [4] .
Desmopressin is available in oral formulations, and an orally disintegrating tablet (ODT) that avoids ingestion of extra fluids overcomes issues related to swallowing difficulty and has improved bioavailability compared with the standard tablet [6] . The pharmacokinetics, efficacy and safety of desmopressin solid tablets have been mia, or symptoms or signs of water intoxication; (3) a deficient plasma vasopressin response to osmotic or non-osmotic stimulation; (4) absence of the posterior pituitary bright spot on midsagittal T1-weighted MRI of the brain. Other key inclusion criteria were maintenance of 24-hour urine volume, urine osmolality, urine specific gravity and serum sodium within normal levels while using desmopressin nasal administration.
Key exclusion criteria included presence or a history of nephrogenic diabetes insipidus (DI) or diabetes mellitus; presence of uncorrected hypothyroidism, hypoadrenalism or hypogonadism; presence of a hypothalamus abnormality leading to thirst disorder; inability to undertake a water-intake restriction; evidence of other health problems unrelated to CDI; and treatment with another investigational product within the past 3 months.
The trial was performed in accordance with the Declaration of Helsinki and approved by the institutional review board/ethics committee for each site. All patients and the legal representative(s) of each patient (if applicable) provided written informed consent.
Study design and procedures
This was a multicenter, open-label dose-titration study. Intranasal desmopressin and desmopressin ODT were supplied by Ferring Pharmaceuticals.
Each eligible patient was admitted to one of five study sites within 30 days of screening for desmopressin ODT dose titration. Patients self-administered intranasal desmopressin on Day 1 and the morning of Day 2. Subsequently, patients received desmopressin ODT 60 μg at noon and night-time of Day 2 and the morning of Day 3. Further dose titration (dosing time, dose to titrate, and time to titrate) to the optimal dose for each individual was in accordance with the investigator's judgement based on urine volume and urine osmolality. Urine specific gravity (g/mL) and urine creatinine (mg/dL) were measured in all urine samples from every void. The start and end of the 24-hour urine volume collections were within 5±2 hours after desmopressin administration, and an average hourly diuresis rate (mL/h) was calculated. Patients continued on their optimal dose for the remainder of the study period, unless a need for adjustment arose.
The dose was increased if clinical symptoms such as polydipsia, polyuria or thirst were observed. Patients were encouraged to drink according to thirst with no other restrictions of water intake. The dose could be increased in increments of 60 μg, ranging from 60 μg reported from a 5-year study in nine Japanese patients with CDI (17-36 years of age) [7] . Mean urine output and urine osmolality, following a single dose of 0.1 mg desmopressin solid tablet, showed the antidiuretic effects of oral desmopressin in this patient population. There was no change in serum sodium levels and no serious safety concerns were identified. In the subsequent 5-year continued administration, well-controlled urine output was observed in eight of the nine patients tested at daily maintenance doses of 0.2 mg to 0.6 mg, and no adverse drug reactions (ADRs) were reported. Though clinical data in Japanese patients are very limited, the dosage and administration of oral desmopressin used in the clinical study conducted by Fukuda et al. [7] were equivalent to those used in overseas studies [8, 9] .
Due to their ease of administration, oral formulations are the preferred treatment route for most patients with CDI [10, 11] . Therefore, it was considered clinically important to develop desmopressin ODT as an alternative to intranasal desmopressin.
The overall purpose of the current study (Clinical Trials.gov NCT01280188) was to demonstrate the efficacy and safety of desmopressin ODT in the treatment of Japanese patients with CDI. The secondary objective was to confirm that patients are controlled to an equivalent degree according to pharmacodynamic parameters when changing from intranasal desmopressin to desmopressin ODT. Every CDI patient requires individual dose titration, depending on the severity of their CDI and also on their individual acceptability of the associated polydipsia/polyuria; therefore this study allowed a flexible dosing regimen. A 12-month follow-up treatment period is reported, and provides valuable safety data on long-term use of desmopressin ODT in Japanese patients with CDI.
Materials and Methods

Patients
Eligible patients were male or female aged 6-75 years with diagnosed CDI (including idiopathic, secondary or familial CDI) defined by evidence of at least two of the following four criteria: (1) Failure to increase urine osmolality above 300 mOsm/kg during a period of fluid deprivation sufficient to raise plasma osmolality and sodium above 295 mOsm/kg and 148 mmol/L, respectively; (2) complete and continuous control of CDI by intranasal desmopressin without 'breakthrough' diuresis, hypernatraemia, hyponatrae-charge. If serum sodium was ≤130 mmol/L the patient was asked to visit the trial site as soon as possible for further evaluation. Patients with serum sodium ≤125 mmol/L were withdrawn from the study immediately.
Additional safety measurements included a standard battery of blood and urine analyses, vital signs and physical examinations. These were conducted during screening, the inpatient dose titration period and at Week 4. All patients who received ≥1 dose of the study drug and had ≥1 safety assessment were included in the safety analyses.
Statistical analysis
A total of at least 20 patients with CDI were to be enrolled at five study centres in Japan. No formal power calculation was performed to assess the sample size for this trial as the number of eligible patients is limited due to the rarity of CDI, with studies typically including 10-14 patients [7, 12, 8] . All primary and secondary endpoints were analysed based on the full analysis set (FAS), which included all exposed patients with at least one efficacy assessment after treatment. All endpoints were summarised descriptively. A stratified analysis by age group (<18, ≥18 years) was performed for each endpoint, using descriptive statistics only. The mean change from baseline to Week 4 for all endpoints was calculated using an ANCOVA analysis adjusting for the baseline value. Missing values were not imputed. A paired t-test and a non-parametric Wilcoxon signed rank sum test of the baseline (nasal desmopressin) and Week 4 (desmopressin ODT titrated to optimal dose) mean urine volume, diuresis rate, urine osmolality and specific gravity were performed post hoc.
Results
Baseline characteristics
A total of 26 eligible patients were registered in the study, but six of these discontinued before receiving desmopressin ODT due to the 2011 Japanese earthquake. Twenty patients entered into the study and received desmopressin ODT, of which 19 patients completed the 4-week treatment period (Fig. 1) . One patient had less than 80% compliance and was excluded from the per protocol set. Baseline characteristics are summarised in Table 1 . Patients were aged 8-71 years (mean 39.6 years), four were <18 years and 12/20 (60%) were male. The duration of diagnosed CDI was 2-24 years, and all patients had been treated with intranasal desmopressin to 180 μg, with an overall maximum daily dose of 720 μg (240 μg three times daily [tid]). The dose was decreased if clinical symptoms suggestive of overdose, such as a body weight gain, malaise, headache, coldness and nausea/vomiting were observed. The dose was also decreased when serum sodium levels were below the lowest value of the normal range (≤136 mmol/L), which were reported as hyponatraemia in this study. The dose could be decreased by 60 μg per dose. When no dose adjustment was required over three consecutive doses, patients were considered titrated to their optimal dose and discharged from the study site for the remainder of the 4-week study period. Treatment compliance was verified at each study visit based on interviews and by review of empty blisters and unused study medication. Patients returned empty medication packages.
A 1-year long-term study extension monitored the safety and maintenance dose of desmopressin ODT, with bimonthly visits.
Endpoints
The primary endpoint was change from baseline to Week 4 in 24-hour urine volume measured 5±2 hours following the final desmopressin ODT dose. Baseline for this endpoint was defined as the mean value at Visit 1 (Day -30±3) and Visit 2 Day 1 (Day -1 to Day 1). Secondary efficacy endpoints included urine output (24-hour urine volume), urine osmolality and urine specific gravity values over time, from intranasal desmopressin treatment time-points: screening visit and Day 1-2 (Day 1 and morning of Day 2), to desmopressin ODT treatment time-point: Week 4. Hourly diuresis rate was also evaluated. Additional secondary endpoints were the percentage of patients within normal range for urine output (<300 mL/h), urine osmolality (>300 mOsm/kg), urine specific gravity (>1.01 g/mL) and 24-hour urine volume (<3000 mL/m 2 body surface area for individuals ≤15 years, <3000 mL for individuals >15 years) at Day 1-2 and Week 4.
Safety and tolerability
Safety and tolerability were monitored at each visit via observation and assessment of adverse events (AEs). AEs were coded by the system organ class and preferred terms using MedDRA (version 14.1), and categorised by severity, seriousness and likelihood of causal relationship to study medication as judged by the investigator.
Serum sodium was measured during screening and on all study visits following treatment and prior to dis- since diagnosis. The aetiologies of CDI and the proportion of patients with anterior pituitary dysfunction are provided in Table 1 . Subsets of patients received hormone replacement therapies including thyroid hormone, glucocorticoid, growth hormone and gonadotropin. All patients were being treated with intranasal desmopressin on Day 1 of the study (median daily dose: 8.5 µg, range 1.875-20 µg).
Efficacy
Primary endpoint: 24-hour urine volume Fig. 2A shows changes from baseline to Week 4 for the primary efficacy endpoint (24-hour urine volume) for the total study population, as well as for those <18 years and ≥18 years of age. There was no statistical difference between Week 4 and baseline mean 24-hour urine volume (paired t-test p=0.10, Wilcoxon rank sum test p=0.14), suggesting equivalent 24-hour concentrating capacity with desmopressin ODT and intranasal therapy.
Secondary endpoints
Diuresis rate, urine specific gravity and urine osmolality are shown in Fig. 2B, 2C and 2D . There was no change in hourly diuresis rate at Week 4 compared with 
Safety
Overall, 11/20 patients experienced 26 AEs. Of these patients, eight were considered to have treatment-emergent AEs (n=11) that were possibly or probably related to the study drug (adverse drug reactions, ADRs; Table  3 ). The most commonly reported ADR was hyponatraemia (7/20 patients, eight events), of which one patient experienced serious hyponatraemia (124 mmol/L) that was classified as a serious AE (SAE) due to hospitalisation, and led to discontinuation. This SAE was judged by investigator and sponsor evaluation potentially to be the consequence of a relative overdose of desmopressin ODT during dose adjustment. Excessive fluid intake after Visit 2 was noted for this patient, which may have exacerbated the hyponatraemia. The other six patients continued desmopressin ODT treatment following a reduction in dose and recovered quickly. However, one patient had a second mild hyponatraemia event with onset after Week 4. All patients with hyponatraemia were ≥18 years old. The frequency of hyponatraemia did not appear to be influenced by the dose of intranasal desmopressin; however, most hyponatraemia events occurred following ≥180 µg desmopressin ODT (6/8 patients) and in patients treated three times a day (6/8 patients). Fig. 2F shows the mean change in serum sodium concentration over time. During dose titration, a mild transient change in serum sodium concentration occurred (-2.7-0.2 mmol/L) from 140.2±2.2 mmol/L at screening. The mean serum sodium concentration nadir occurred on Day 4 of the in-hospital dose titration period (137.4 mmol/L). Overall, the mean change in serum sodium concentration from screening to Week 4 was -0.3±3.1 mmol/L, and changes in serum sodium levels during the study were not significant.
Results of 12-month follow-up safety data
All 19 patients who completed the 4-week study continued into the long-term safety study, with 19 patients completing 6-months follow-up and 17 patients completing the full 12-month extension. Two patient withdrawals, due to nasopharyngitis and rib fracture, respectively, were not considered to be related to the study drug. The overall median daily dose was constant (180 µg) throughout the 12-month extension study. A total of 13 patients did not change the daily dose during the study extension. Two patients increased the daily dose due to increase in urine volume and four patients decreased the daily dose due to reduction in serum sodium levels. Overall, six events of hyponatrabaseline (paired t-test p=0.10, Wilcoxon rank sum test p=0.14).
Urine specific gravity remained similar to baseline at Week 4 (mean change: 0.0029±0.0087 g/mL; paired t-test p=0.12, Wilcoxon rank sum test p=0.06). Urine osmolality was not significantly different at Week 4 (711.7±198.6 mOsm/kg) compared with baseline (597.2±212.0 mOsm/kg, average of values at screening visit and Day -1 to Day 1, paired t-test p=0.11, Wilcoxon rank sum test p=0.08). The urine osmolality of one patient at Week 4 was 93 mOsm/kg, which suggests little urine concentrating activity, although baseline and Week 2 urine osmolality values were within normal ranges (562 and 641 mOsm/kg, respectively). Similar changes in secondary endpoints were seen in patients <18 years compared with those ≥18 years of age, although no formal testing was performed due to the low patient numbers.
Pharmacodynamic parameters within the normal range
The same or a greater proportion of patients were within the normal range for all pharmacodynamic parameters at Week 4 compared with Day 1-2 (Fig. 2E) . The hourly diuresis rate, of all patients, was maintained within the normal range at Day 1-2 and Week 4. The endpoint with the greatest proportion of patients outside the normal range was 24-hour urine volume (~84%); however, this value was unchanged from nasal desmopressin to desmopressin ODT administration. All patients ≤15 years were within the normal range of 24-hour urine volume measurement at Day 1-2 and Week 4 (data not shown).
Desmopressin dose and administration frequency
Individual, mean and median desmopressin dose and dose frequency are shown in Table 2 . A total of 20 patients received intranasal therapy at a median daily dose of 8.50 μg/day (range: 1.875-20 μg/day) on Days 1-2.
Although patients were still under dose titration up to Week 2, the majority of patients maintained the same desmopressin ODT dose between completion of on-site dose titration and Week 2. The median desmopressin ODT dose was maintained between Week 2 and Week 4, with patients receiving desmopressin ODT 120-360 μg/day, in either two or three doses. The ratio of mean daily dose of intranasal desmopressin (on Day 1) to desmopressin ODT (on Week 4) was approximately 1:24. However, there was a wide range of desmopressin intranasal: desmopressin ODT mean daily dose ratios across individuals, to maintain adequate antidiuresis, with ratios from 1:12 to 1:96 observed in this study (Table 2) . , duration unknown as AE onset occurred at end of study emia were reported. One patient experienced hyponatraemia three times but all reductions in serum sodium were mild (132-133 mmol/L). In another patient the serum sodium levels decreased to 126 mmol/L, but this incident was judged to be due to the patient missing a scheduled dose of glucocorticoid hormone on that day. None of the observed reductions in serum sodium concentration were accompanied by any overt symptoms, and all were judged to be non-serious, with rapid return to normal levels with or without the need for dose modification. Overall, long-term desmopressin ODT treatment was well tolerated.
Discussion
Desmopressin is the therapy of choice in the treatment of CDI [5] . Desmopressin was initially introduced as parenteral and intranasal formulations, but is now available in oral formulations, including sublingually administered ODT [5, 13] . Previous studies have shown that a switch from intranasal to oral desmopressin achieves good antidiuretic control and is well tolerated in adults [5] and children [10, 11] . Large-scale or placebo-controlled clinical studies in patients with CDI are not feasible, because CDI is rare, and the use of placebo is not ethically acceptable due to the nature of the disease. This multicenter, open-label dose-titration study demonstrated that the oral lyophilisate formulation of desmopressin, desmopressin ODT, maintains antidiuresis on switching from intranasal desmopressin in Japanese patients with CDI. Desmopressin ODT was well tolerated, with reduction in serum sodium concentration being the most frequently reported ADR, as seen in previous clinical trials with desmopressin [5] . While reductions in serum sodium concentration occurred early following switching from intranasal desmopressin to desmopressin ODT in this study, recovery was observed after dose modification or discontinuation of treatment in all cases, confirming the overall safety of desmopressin ODT in the treatment of CDI. Post-marketing data across all indications have shown a lower risk of hyponatraemia for oral formulations compared with the nasal formulation of desmopressin, leading to recommendation of oral formulations over the nasal formulation [13] . Large individual variation in intranasal drug absorption may explain unwanted increases in antidiuretic duration of action and thereby the slightly higher risk of hyponatraemia with the nasal formulation [13] .
There are a number of disadvantages associated with the intranasal desmopressin compared with oral formulations of desmopressin. There is greater variability in dosing using intranasal desmopressin, and absorption may be altered in patients with nasal mucosa changes [5] . Furthermore the intranasal formulation requires refrigeration to ensure long-term stability [5] . A paediatric study examining switching from desmopressin nasal spray to desmopressin oral tablets in patients with CDI reported that all patients preferred the tablet compared with the nasal formulation [10] . Nevertheless, the intranasal formulation remains of benefit in some patients including infants with CDI [14] because the wide range of different dose strengths allows individualised administration of the dose required to obtain control of water balance in each patient.
Previous studies suggest that a 19 times greater dose of desmopressin oral tablet compared with intranasal desmopressin is required to maintain adequate antidiuretic control [7] and that following switching patients were stable with adequate water turnover on doses of 100-400 µg desmopressin tablet tid [10] . Therefore, dose titration was initiated in this study with desmopressin ODT 60 µg tid. However, another study in patients with CDI demonstrated that the duration of antidiuretic action of desmopressin 500 ng IV, which corresponds to desmopressin ODT 160 µg, was between 11 and 15 h [15] . In this study, some younger patients, for whom it was not easy to take desmopressin ODT in the daytime at school, were administered with a relatively high dose of desmopressin ODT bid, without negative effects. These data suggest that there is a need for individual dose titration as previously reported [8] .
Desmopressin ODT demonstrated the same level of antidiuretic control as intranasal desmopressin, with the same proportion of patients within the normal range for all pharmacodynamic endpoints at Week 4, following desmopressin ODT therapy compared with intranasal desmopressin therapy at Day 1-2. Although the overall patient numbers were small, desmopressin ODT was similarly efficacious to intranasal desmopressin in the younger (<18 years) and older (≥18years) groups. Nevertheless, there was wide variation of the intranasal desmopressin:ODT desmopressin ratios required to maintain similar levels of antidiuretic effect, ranging from 1:12 to 1:96. These data suggest that it is not possible to predict the required desmopressin ODT dose in a patient previously managed with intranasal desmopressin, and highlight the necessity of individ-other studies in CDI populations confirming that desmopressin in different formulations and bioequivalent strengths is an effective treatment for CDI [7, 8, 16, 17] . This study supports the introduction of desmopressin ODT as the first-line therapy for antidiuretic control in patients with CDI.
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Hiroshi Arima and Yutaka Oiso are paid consultants of Ferring Pharmaceuticals. ual dose adjustment based on observed pharmacodynamic parameters. This is further demonstrated by the individual patient data in this study that show no direct dose correlation between the two formulations. We should be aware that some patients with CDI were well managed with a lower dose of desmopressin ODT, suggesting that the treatment should start with a minimum dose of desmopressin ODT in order to avoid hyponatraemia, particularly in outpatients. The dose may then be cautiously titrated in increments according to the clinical antidiuretic response. During the preparation of this manuscript, desmopressin ODT has been approved in Japan. It is of note that the label approved by the Pharmaceutical and Medical Devices Agency indicates that the intended level of efficacy may not be achieved with postprandial administration. Therefore it is desirable to avoid administration of desmopressin ODT immediately after eating.
While seven out of 20 patients experienced hyponatraemia in this study, the incidence of hyponatraemia during intranasal desmopressin therapy prior to the trial was not recorded. As patients with CDI are likely to be switched from intranasal to oral desmopressin, studies to examine the incidence of hyponatraemia in both formulations should be undertaken in the near future.
In conclusion, this study provides evidence of the efficacy and long-term safety of desmopressin ODT following individual dose titration from intranasal desmopressin therapy in the treatment of Japanese patients with CDI. These findings are consistent with
